Search

Your search keyword '"Villeval, Jean-Luc"' showing total 396 results

Search Constraints

Start Over You searched for: Author "Villeval, Jean-Luc" Remove constraint Author: "Villeval, Jean-Luc"
396 results on '"Villeval, Jean-Luc"'

Search Results

1. Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms

2. Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis

4. Supplementary Table from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

5. Data from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

6. Supplementary Data from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

7. Erythrocyte-derived microvesicles induce arterial spasms in [JAK2.sup.V617F] myeloproliferative neoplasm

11. PPAR[gamma] agonists promote the resolution of myelofibrosis in preclinical models

12. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice

13. Data from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

14. Supplementary Data from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

15. Supplementary Table from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

16. Supplementary Tables 1 to 11 from Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia

17. Data from Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia

18. Supplementary Figures and Legends from Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia

20. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice

22. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

23. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene

24. In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

25. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms

27. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes

29. Activating mutations in human acute megakaryoblastic leukemia

31. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

32. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy

33. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.

38. 1017 – INVESTIGATING THE MECHANISMS OF IFNALPHA THERAPY IN JAK2V617F AND CALR MUTATED MYELOPROLIFERATIVE NEOPLASMS

40. Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia

43. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression

48. Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Catalog

Books, media, physical & digital resources